Your AI-Trained Oncology Knowledge Connection!
Data presented at 2022 SGO from the phase 2 OVARIO trial show promise of niraparib plus bevacizumab in high-risk ovarian cancer treated with frontline platinum-based chemotherapy.
Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.
Results of the phase 1 NRG-GY017 trial show promise of atezolizumab as an immune primer in locally advanced cervical cancer.
Patients with BRCA-mutant, homologous repair deficiency–positive advanced resectable ovarian cancer may benefit from treatment with neoadjuvant niraparib, according to early results of a phase 2 trial reported at 2022 SGO.
Jhalak Dholakia, MD, discusses the promising neoadjuvant combination of of carboplatin and mirvetuximab soravtansine in folate receptor α–positive advanced-stage ovarian, fallopian tube, or primary peritoneal cancer.
Olaparib and non-platinum chemotherapy produced similar overall survival results when treating patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations.
No differences in overall and progression-free survival were observed at the GOG-0252 trial update among patients with ovarian cancer who were treated with intravenous or intraperitoneal chemotherapy plus bevacizumab.
Updated results from the KEYNOTE-826 study show a favorable risk-benefit ratio for pembrolizumab plus chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer.
Olaparib maintenance therapy will be investigated after receiving first-line chemotherapy for patients with BRCA1/2 wild-type advanced ovarian cancer.
An anti-TIGIT/anti–PD-1 combination approach with ociperlimab plus tislelizumab will be examined in a phase 2 study of patients with previously treated recurrent or metastatic cervical cancer.
An overview of the phase 3 ARTISTRY-7 trial involving combination therapy with nemvaleukin alfa and pembrolizumab was presented at 2022 SGO.
The ongoing KEYNOTE-B21 trial aims to determine if pembrolizumab plus adjuvant chemotherapy with or without radiotherapy will improve disease-free survival and overall survival in patients with newly diagnosed endometrial cancer.
Patients with unresectable or metastatic melanoma can now receive treatment with nivolumab and relatlimab-rmbw following its approval by the FDA.
Long-term progression-free survival was associated with various clinical and molecular factors in patients receiving olaparib who had platinum-sensitive relapsed ovarian cancer and no germline mutations in BRCA1/2.
To assess the oregovomab combination, a phase 3 trial has launched for patients with advanced epithelial ovarian cancer.
The phase 2 CC-ANNIE trial was launched in China investigating anlotinib plus sintilimiab for recurrent platinum-resistant ovarian clear cell carcinoma.
The FoundationOne CDx diagnostic was approved as a companion diagnostic to help identify EGFR 19 deletions or exon 21 alterations in non–small cell lung cancer.
Catherine Watson, MD, discussed the main results and key takeaway from a trial analyzing streamlined and traditional education practices for patients with ovarian cancer.
Patients with recurrent ovarian cancer experienced a longer overall survival and time to next treatment when receiving second-line PARP maintenance compared with active surveillance.
Recently presented data from the KEYNOTE-091 trial show a trend toward survival benefit with adjuvant pembrolizumab in patients with resected non–small cell lung cancer, especially in patients with PD-L1–positive disease.
At the recent 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Jean Hoffman-Censits, MD, reviews advances in the use of systemic therapy to aid surgical management of bladder cancer.
Investigators believe that neoadjuvant chemotherapy may play a role in mandibular prevention in patients with oral cavity cancer.
Results presented at an ESMO Virtual Plenary in March 2022 show that maintenance therapy with selinexor decreased the risk of progression or death for patients with advanced or recurrent endometrial cancer.
At a recent conference, Robert Dreicer, MD, MS, MACP, FASCO, offered his advice regarding the use of androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer.
Patients with ovarian clear cell cancer did not seem to derive additional benefit after undergoing retroperitoneal lymphadenectomy.
The KEYNOTE-775 trial found that lenvatinib plus pembrolizumab prolonged progression-free survival compared with chemotherapy for patients with endometrial cancer.
For Kidney Cancer Awareness Month, Toni K. Choueiri, MD, spoke with CancerNetwork® about ongoing trials clinicians need to be aware of.
The second follow-up analysis of the OlympiA trial showed a statistically significant improvment in overall survival with use of adjuvant olaparib to treat germline BRCA1/2 mutation–associated breast cancer.
Gennady Bratslavsky, MD, discusses the ever-changing field of treatment options for renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.
Kira MacDougall, MD, and co-investigators, research the importance of peripheral biomarkers in patients with advanced non–small cell lung cancer who are treated with pembrolizumab.
